If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Type 2 Diabetes, Decision Resources is offering an exclusive analyst call entitled Avandia Makes Headlines Again: How Will the Renewed Controversy Impact the Type 2 Diabetes Drug Market? Because this presentation will feature report updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. GlaxoSmithKline’s Avandia has been on the market for treatment of type 2 diabetes for more than a decade and in 2006, the total franchise—including Avandamet and Avandaryl—garnered nearly $2.5 billion in sales in the United States alone. However, since the 2007 publication of a controversial meta-analysis which suggested a possible increased risk of myocardial infarction associated with this drug, Avandia franchise sales have steadily declined, reaching a new low of approximately $700 million in the U.S. last year. Recently released findings from an investigation by the U.S. Senate Finance Committee have thrust Avandia under the spotlight once again, leading some to question whether the drug should be withdrawn. Furthermore, internal reports from the U.S. Food and Drug Administration (FDA) that were made public at the same time as the U.S. Senate report show disagreement within the FDA about whether Avandia should remain on the market. Because of these differing opinions, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet in July to discuss the results of Avandia’s post-marketing trials, including the RECORD trial which, as reported last year, showed no significant increase in the risk of myocardial infarction associated with Avandia. Following these recent events, Decision Resources interviewed U.S. and European thought leaders and, combined with our own analysis, insights from these interviews will be discussed in this presentation. This 10-minute analyst call, presented by Analyst Christine Helliwell, Ph.D., will answer the following questions:
Dr. Helliwell will conduct a live Q & A session after the presentation. Registration Avandia Makes Headlines Again: How Will the Renewed Controversy Impact the Type 2 Diabetes Drug Market? March 5, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
